Loading patent…
AssigneeJanssen Pharmaceutica NV
InventorsMarc Hubert Mercken, Marianne Borgers, Marc, Maria, Pierre, Pelagie Vandermeeren, Bianca Julia J Van Broeck
Estimating the term…
The present invention provides monoclonal antibodies which specifically recognize the shorter Aβ peptides obtained after cleavage of the APP protein mediated by γ-secretase, i.e. the Aβ-peptide fragments Aβ1-37, Aβ3-37, Aβ3p-37, Aβ1-37 and Aβ11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the Aβx-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an Aβx-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of Aβx-37 peptides in a sample, such as a biological sample.
A monoclonal antibody which specifically recognizes Aβx-37 peptide.
Method for the determination or detection of the presence of Aβx-37 peptides in a sample, comprising contacting the sample with the a monoclonal antibody which specifically recognizes Aβx-37 peptide and determining whether an immune complex is formed between said monoclonal antibody and said Aβx-37 peptide.
(canceled)
A method for monitoring treatment of β-amyloid-related diseases, comprising the steps of:
An immunoassay kit for the diagnosis, progression monitoring or treatment monitoring of β-amyloid-related diseases comprising the monoclonal antibody which specifically recognizes Aβx-37 peptide which is detectable labeled and a carrier means for the monoclonal antibody.
Dependencies are inferred from the claim text.